TANGO - Targeted Augmentation of Nuclear Gene Output - Antisense Therapy

PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit

Updated: 05/22/2019

Pipeline Type

New Drugs in Development

Phase Of Development

Preclinical

Sponsors and Collaborators

Stoke Therapeutics

Mechanism of Action

Mechanism Description

Antisense Therapy - TANGO - Targeted Augmentation of Nuclear Gene Output - targeted to increase SCN1A RNA and increase Sodium Channel Nav1.1 expression

Populations Tested In

Dravet Mouse Model

Other Resources

Special FDA Designation

Nonprofit or Government Support

N/A

Nonprofit or Government Support Description

N/A

Previous Presentations

Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
AEDD XV May 2019

Location of Clinical Trials

N/A

Clinical Trial link

Sign Up for Emails

Stay up to date with the latest epilepsy news, stories from the community, and more.